Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Trial in progress: Natural killer (NK) cells with TGFβ receptor I inhibitor vactosertib and IL-2 in patients with metastatic colorectal cancer or hematologic malignancies.
Authors
J. Eva Selfridge
University Hospitals, Cleveland Medical Center - Seidman Cancer Center, Cleveland, OH;
J. Eva Selfridge , David L Bajor , AMR MOHAMED , Sakti Chakrabarti , Jane Reese , Hillard M. Lazarus , Afshin Dowlati , Amit Mahipal , David Wald
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05400122
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS273)
DOI
10.1200/JCO.2023.41.4_suppl.TPS273
Abstract #
TPS273
Poster Bd #
P15
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.
First Author: Chantale Bernatchez
Poster
2023 ASCO Annual Meeting
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Rosa Nadal
Poster
2022 ASCO Annual Meeting
A first-in-human, multicenter, phase 1/2, open-label study of XTX202, a masked and tumor-selective recombinant human interleukin-2 (IL-2) protein, in patients with advanced solid tumors.
First Author: Meredith McKean
Poster
2022 ASCO Annual Meeting
Efficacy and safety of autologous expanded tumor infiltrating lymphocytes (TILs) in multiple solid tumors.
First Author: Rodabe Navroze Amaria